These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 156026)
41. Risk factors that may influence development of side effects of gold sodium thiomalate. Kay EA; Jayson MI Scand J Rheumatol; 1987; 16(4):241-5. PubMed ID: 2957787 [TBL] [Abstract][Full Text] [Related]
43. [Studies of protein clearance in patients treated with and without gold preparations in rheumatoid arthritis]. Gräfenstein K Z Gesamte Inn Med; 1987 Jan; 42(2):56-8. PubMed ID: 3107230 [TBL] [Abstract][Full Text] [Related]
44. Renal changes in patients with rheumatoid arthritis treated with sodium thiomalate and D-penicillamine. Domljan Z; Borso G; Marinković M; Winter Fudurić I; Pucar I; Cikes N Acta Med Iugosl; 1987; 41(5):363-72. PubMed ID: 3128058 [No Abstract] [Full Text] [Related]
49. [The Tauredon treatment of rheumatoid arthritis patients: its efficacy and tolerance when used long term]. Murav'ev IuV; Nasonova VA; Ivanova MM; Taukumova LA Ter Arkh; 1996; 68(5):16-8. PubMed ID: 9082589 [No Abstract] [Full Text] [Related]
50. Chrysotherapy in rheumatoid arthritis with particular emphasis on the effect of chrysotherapy on radiographical changes and on the optimal time of initiation of therapy. Luukkainen R Scand J Rheumatol Suppl; 1980; 34():1-56. PubMed ID: 6791272 [No Abstract] [Full Text] [Related]
51. Ultrastructure of the skin of patients treated with sodium aurothiomalate. Ghadially FN; DeCoteau WE; Huang S; Thomas I J Pathol; 1978 Feb; 124(2):77-83. PubMed ID: 152806 [TBL] [Abstract][Full Text] [Related]
52. A 10 year follow up of parenteral gold therapy in patients with rheumatoid arthritis. Bendix G; Bjelle A Ann Rheum Dis; 1996 Mar; 55(3):169-76. PubMed ID: 8712879 [TBL] [Abstract][Full Text] [Related]
53. Observations on the clinical and therapeutic aspects of gold induced thrombocytopenia. Barton JJ; Burke JP; Casey EB; McCann SR Ir Med J; 1985 Jun; 78(6):167-9. PubMed ID: 3924856 [No Abstract] [Full Text] [Related]
54. Gold-induced immune thrombocytopenia in the dog. Bloom JC; Blackmer SA; Bugelski PJ; Sowinski JM; Saunders LZ Vet Pathol; 1985 Sep; 22(5):492-9. PubMed ID: 3931338 [TBL] [Abstract][Full Text] [Related]
55. Does hypothyroidism predispose to gold-induced thrombocytopenia? Hunter JA; Capell HA Scott Med J; 1982 Jul; 27(3):247-9. PubMed ID: 6810460 [TBL] [Abstract][Full Text] [Related]
56. Audit of full blood count monitoring in patients on longterm gold therapy for rheumatoid arthritis. Cervi PL; Wright P; Casey EB Ir J Med Sci; 1992 Mar; 161(3):73-4. PubMed ID: 1517060 [TBL] [Abstract][Full Text] [Related]
57. Immunogenetic and racial determinants of gold toxicity in rheumatoid arthritis. Fraser PA; Stern SH; Coblyn JS; Weinblatt ME; Holdsworth DE; Green P; Shriner S; Mindnich D; Larson M J Natl Med Assoc; 1988 Feb; 80(2):162-5. PubMed ID: 2977188 [TBL] [Abstract][Full Text] [Related]
58. Neutropenia occurring during the course of chrysotherapy: a review of 25 cases. Aaron S; Davis P; Percy J J Rheumatol; 1985 Oct; 12(5):897-9. PubMed ID: 3936931 [TBL] [Abstract][Full Text] [Related]
59. Gold therapy for rheumatoid arthritis. Spruck M Am J Nurs; 1979 Jul; 79(7):1246-8. PubMed ID: 156500 [No Abstract] [Full Text] [Related]
60. Can gold therapy be used more safely in rheumatoid arthritis? Adverse drug reactions are more likely in patients with nodular disease, independent of HLA-DR3 status. Shah P; Griffith SM; Shadforth MF; Fisher J; Dawes PT; Poulton KV; Thomson W; Ollier WE; Mattey DL J Rheumatol; 2004 Oct; 31(10):1903-5. PubMed ID: 15468351 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]